Protocol Ledger

NCT06157892 · Phase II · ACTIVE NOT RECRUITING

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Interventional Phase II clinical trial protocol NCT06157892 sponsored by Pfizer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-05-20 Enrollment: 54 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06157892
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)54 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06157892
Protocol FieldVerified Registry Value
NCT IdentifierNCT06157892
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment54 participants (ACTUAL)
Registered Start Date2024-05-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI